234 related articles for article (PubMed ID: 28844713)
1. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
Qin H; Liu X; Li F; Miao L; Li T; Xu B; An X; Muth A; Thompson PR; Coonrod SA; Zhang X
Cancer Lett; 2017 Nov; 409():30-41. PubMed ID: 28844713
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
4. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
[TBL] [Abstract][Full Text] [Related]
5. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
6. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
7. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
8. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
9. Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis.
Lemieux E; Bergeron S; Durand V; Asselin C; Saucier C; Rivard N
Int J Cancer; 2009 Oct; 125(7):1575-86. PubMed ID: 19462441
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
11. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
14. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.
Khan S; Shukla S; Sinha S; Lakra AD; Bora HK; Meeran SM
Int J Biochem Cell Biol; 2015 Jan; 58():1-16. PubMed ID: 25448414
[TBL] [Abstract][Full Text] [Related]
15. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
16. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
[TBL] [Abstract][Full Text] [Related]
17. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
18. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
[TBL] [Abstract][Full Text] [Related]
19. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
20. Eupolyphaga sinensis Walker Ethanol Extract Suppresses Cell Growth and Invasion in Human Breast Cancer Cells.
Zhan Y; Zhang H; Liu R; Wang W; Qi J; Zhang Y
Integr Cancer Ther; 2016 Mar; 15(1):102-12. PubMed ID: 26242891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
